Valo: adding tumor antigens to oncolytic viruses

Valo’s platforms use physical interactions for viral display of tumor antigens without genetic engineering

With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology companies.

Oncolytic viruses kill cancer cells by lysing the cells, and are engineered to amplify antitumor immune responses through expression of immuno-stimulatory genes.

By adding targeted antigens to viral surfaces, Valo Therapeutics Ltd. thinks the viruses can get a more specific antitumor response.

CEO

Read the full 665 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE